Johnson & Johnson (NYSE:JNJ) was the target of some unusual options trading on Wednesday. Traders bought 11,192 put options on the company. This is an increase of approximately 244% compared to the typical volume of 3,249 put options.

Shares of Johnson & Johnson (NYSE JNJ) opened at 131.39 on Friday. The company has a market capitalization of $352.65 billion, a PE ratio of 22.23 and a beta of 0.79. The stock’s 50 day moving average price is $132.79 and its 200 day moving average price is $129.43. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.74 EPS. On average, equities research analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

In related news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in the company. Lenox Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. Landmark Financial Advisors LLC increased its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC increased its position in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after purchasing an additional 9 shares during the last quarter. Premier Asset Management LLC increased its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares during the last quarter. Finally, Lbmc Investment Advisors LLC increased its position in shares of Johnson & Johnson by 0.4% during the 1st quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after purchasing an additional 14 shares during the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.

A number of research analysts recently commented on JNJ shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 price target on shares of Johnson & Johnson in a research note on Friday, June 2nd. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target for the company in a research note on Monday, May 29th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 15th. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, UBS AG reiterated a “buy” rating and issued a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $135.29.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson Sees Unusually High Options Volume (JNJ)” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/23/johnson-johnson-sees-unusually-high-options-volume-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.